Redhill Biopharma Ltd. (NASDAQ:RDHL – Get Free Report) was the target of a significant decline in short interest in July. As of July 15th, there was short interest totaling 19,996 shares, a decline of 35.8% from the June 30th total of 31,149 shares. Approximately 0.4% of the company’s stock are short sold. Based on an average daily volume of 85,870 shares, the days-to-cover ratio is currently 0.2 days.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings upgraded shares of Redhill Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, May 6th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.
Read Our Latest Stock Report on RDHL
Redhill Biopharma Price Performance
Institutional Investors Weigh In On Redhill Biopharma
A hedge fund recently bought a new position in Redhill Biopharma stock. Yorkville Advisors Global LP acquired a new stake in shares of Redhill Biopharma Ltd. (NASDAQ:RDHL – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 386,593 shares of the biotechnology company’s stock, valued at approximately $398,000. Redhill Biopharma makes up approximately 0.3% of Yorkville Advisors Global LP’s portfolio, making the stock its 19th biggest holding. Yorkville Advisors Global LP owned about 7.57% of Redhill Biopharma as of its most recent SEC filing. Institutional investors and hedge funds own 7.20% of the company’s stock.
About Redhill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.
RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.
Featured Articles
- Five stocks we like better than Redhill Biopharma
- Everyone’s Focused on China—But That’s Not ASML’s Biggest Risk
- Chipotle Mexican Grill Stock Rallies as Q2 Results Top Fears, Guidance Rises
- L3Harris’ Record Backlog Makes Its Stock Sell-Off Look Overdone
- Quantum Earnings Could Decide Whether the Sector’s Sell-Off Has Gone Too Far
Receive News & Ratings for Redhill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
